Hyperlipoproteinaemia(a) – apheresis and emerging therapies
نویسندگان
چکیده
منابع مشابه
Hyperlipoproteinaemia(a) – apheresis and emerging therapies
A high level of lipoprotein(a) (Lp(a)) is recognized as an independent and additional cardiovascular risk factor contributing to the risk of early onset and progressive course of cardiovascular disease (CVD). All lipid lowering medications in use mainly lower low density lipoprotein-cholesterol (LDL-c) with no or limited effect on levels of Lp(a). Niacin, the only component lowering Lp(a), is f...
متن کاملConventional apheresis therapies: a review.
This article reviews advances in the scientific basis and medical practice of plasmapheresis and cytapheresis therapies. Newly-characterized autoantibodies in neuromyelitis optica, Guillain-Barre variants, anti-neutrophil cytoplasmic antibody (ANCA) vasculitides, etc., exemplify the modern molecular biology which now provides a rigorous framework of understanding for the clinical practice of pl...
متن کاملEmerging Drug Therapies for Heart Failure
Heart failure is associated with high morbidity and mortality and is proving to be an economic burden in developing countries. A number of therapeutic agents are presently employed in heart failure; but they are not sufficient to control symptoms of heart failure. Moreover, the prevalence of chronic heart failure is progressively increasing and thus there is a continuing need to develop effecti...
متن کاملEmerging therapies.
The results of the European Cooperative Acute Stroke Study III (ECASS III) provide an important advance for the field of acute stroke therapy. The study was well-designed and conducted. The trial provides unequivocal and straightforward evidence that treatment with intravenous (IV) tissue plasminogen activator (tPA) initiated 3 to 4.5 hours after the onset of ischemic stroke improves 90-day out...
متن کاملEmerging Therapies
Indirect comparisons of CAPRIE, ESPS-2, and MATCH trials led many stroke experts to favor the combination of aspirin and extended-release dipyridamole (ASA/ERD) over clopidogrel as the preferred antiplatelet therapy for secondary stroke prevention.1–3 The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) study, a 2 2 factorial, double-blind, event-driven, active and placebo-c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Research in Cardiology Supplements
سال: 2017
ISSN: 1861-0706,1861-0714
DOI: 10.1007/s11789-017-0083-2